Compare TORM plc (TRMD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs GeneDx Holdings Corp — how do they compare? TORM plc trades at $40.6 (market cap $4.12B), while GeneDx Holdings Corp trades at $67.59 (market cap $2.02B). The key difference: TORM plc is far larger — about 2× GeneDx Holdings Corp's market cap, and TORM plc pays a 11.03% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold TORM plc for 23 Days and GeneDx Holdings Corp for 19 Days on average.
| TRMD | WGS | |
|---|---|---|
Market Cap | $4.12B | $2.02B |
Volume | 2,863,116 | 734,640 |
Sector | Industrials | Health |
52-Week High | $41.05 | $167.51 |
52-Week Low | $19.39 | $34.51 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | $4.83B | $2.05B |
Dividend Yield | 11.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $40.54, up 4.16% today, with a bullish technical signal from moving averages and strong profitability metrics including a 35.52% net income margin and 26.84% ROE. Recent earnings showed a Q2 2026 miss but a Q4 2025 beat, while 2026 revenue is projected to grow to $1.8B. A $2.40 dividend is scheduled for September 2026, and analyst consensus is unanimously bullish with 3 buy ratings.
The outlook is positive given robust fundamentals and analyst support, but risks include spot rate volatility in the tanker market and recent insider selling. Upside potential hinges on sustained freight rates, while a downturn could pressure earnings. The stock presents a value opportunity with a low P/E of 6.59, though cyclical industry exposure warrants caution.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
